Next-generation ultra-long-acting therapeutics (yearly injectables) can provide durable solutions for the treatment and prevention of HIV and other chronic disorders.
TARGETING HIV INTEGRASE
Integrase inhibitors (INSTIs) are a core component of the HIV treatment standard of care, and are emerging as the most efficacious approved option in prevention. Our ultra-long-acting INSTIs have the potential to be best in class.
A CRISPR BASED CURE FOR HIV
CRISPR based editing is the only method to have demonstrated complete eradication of HIV in a living animal. Our next generation approach targets the highly conserved TAT gene as a cure.
Our ultra-long acting antiretroviral portfolio is a multi-class arsenal for HIV treatment and prevention regimens. Our agents are de-risked by existing antiretrovirals that are proven to work at target drug exposure levels.